diagnosis
The diagnosis of B-CLL is established by the following criteria.
The diagnosis of CLL requires the presence of ‡5000 B lymphocytes/ll in the peripheral blood for the duration of at least 3 months. The clonality of the circulating B lymphocytes needs to be confirmed by flow cytometry. The leukaemia cells found in the blood smear are characteristically small, mature lymphocytes with a narrow border of cytoplasm and a dense nucleus lacking discernable nucleoli and having partially aggregated chromatin.
CLL cells co-express the T-cell antigen CD5 and B-cell surface antigens CD19, CD20 and CD23. The levels of surface immunoglobulin, CD20 and CD79b are characteristically low compared with those found on normal B cells. Each clone of leukaemia cells is restricted to expression of either j or k immunoglobulin light chains.
In contrast, the leukaemia cells of mantle cell lymphoma, despite also expressing B-cell surface antigens and CD5, generally do not express CD23. Other lymphoma entities to be separated are marginal zone lymphoma and immunocytoma. 
staging and risk assessment
The median survival at diagnosis varies between 1 and >10 years. Two clinical staging systems are used. In Europe, the Binet staging system is more widely used. It separates three groups of different prognosis (Table 1) . With the new treatment options available, the overall survival of patients with advanced stages seems to have improved.
Additional prognostic markers are available to predict the prognosis of patients with CLL, in particular at early stages. Patients with a detectable del(17p) (5%-10% of patients) have the poorest prognosis with a median overall survival time of 2-3 years. Another poor prognostic marker is the del(11q), which is found in $20% of the patients. However, the poor outcome of patients with del(11q) is overcome by chemoimmunotherapy with fludarabine, cyclophosphamide, rituximab (FCR) (see below).
About 50% of CLL patients present with an unmutated IGHV status. These patients have a significantly shorter overall survival time and time to initiation of treatment. The expression of CD38, ZAP70 seems to correlate with the IGHV mutational status to some extent. In contrast to molecular cytogenetics (FISH), these analyses should not influence the treatment indication in CLL. Their value needs further investigation in clinical trials [III, C]. Patients showing a chromosomal defect del(17p) frequently do not respond to conventional chemotherapy with fludarabine or FC. Even after FCR therapy, progression free survival of these patients remains short. Therefore, these patients with sufficient fitness should be offered allogeneic stem cell transplantation within clinical trials [III, B].
second-line chemotherapy
The first-line treatment may be repeated, if the relapse or progression occurs at least 12 months after the initial therapy and 24 months after immunochemotherapy [III, B] .
If the relapse occurs within 12 months after monotherapy or 24 months after immunochemotherapy, or if the disease does not respond to first-line monotherapy, the therapeutic regimen needs to be changed to one of the following options [III, B]. Alemtuzumab-containing regimen followed by allogeneic stem cell transplantation in physically fit patients. FCR for patients relapsed or refractory to first-line therapy with an alkylating agent. Alemtuzumab-or bendamustine-containing regimen in physically non-fit patients without del(17p). In these patients an attempt with high-dose ofatumomab or rituximab with high-dose steroids can be made. Alemtuzumab in physically non-fit patients with del(17p).
In order to achieve better efficacy in patients with bulky disease alemtuzumab may be combined with fludarabine or steroids.
Allogeneic stem cell transplantation is the only curative therapy and is indicated in high risk [del(17p), del(11q)] and/ or refractory disease. Autologous HSCT does not seem to yield better results than immunochemotherapies and should be abandoned [III, B]. Detection of minimal residual disease (MRD) by four-colour flow cytometry has prognostic impact on the duration of remission. Patients who have become MRD negative after the end of treatment have a significantly longer response duration. However, the clinical consequences of a MRD signal after the end of therapy are unclear. Therefore, the analysis of MRD should be performed in clinical trials, but not in general routine.
follow-up
Follow-up of asymptomatic patients should include a blood cell count, and the palpation of lymph nodes, liver and spleen every 3 months. Special attention should be paid to the appearance of autoimmune cytopenias (autoimmune haemolytic anaemia, autoimmune thrombocytopenia), which occur in 10%-15% of CLL patients.
Patients with CLL have a two-to sevenfold increase risk of developing secondary malignancies, including secondary MDS or AML as well as solid tumors. 
